A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301
Latest Information Update: 27 Dec 2021
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 08 Jan 2021 Status changed from active, no longer recruiting to completed.
- 28 Sep 2020 Planned End Date changed from 31 Jul 2020 to 30 Apr 2021.
- 28 Sep 2020 Planned primary completion date changed from 31 Jul 2020 to 30 Apr 2021.